程序性死亡受体-1和程序性死亡配体-1检查点抑制相关的大疱性类天疱疮：一项倾向匹配的回顾性队列研究。 - Suppr | 超能文献

Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study.

作者信息

Sarkovics Katelyn, Kolodney Joanna A, Kolodney Michael S

机构信息

Department of Dermatology, West Virginia University, Morgantown, WV, USA.

Department of Medicine, Division of Hematology-Oncology, West Virginia University, Morgantown, WV, USA.

出版信息

Br J Dermatol. 2024 Jul 16;191(2):299-300. doi: 10.1093/bjd/ljae172.

DOI:10.1093/bjd/ljae172

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Programmed death receptor-1 and programmed death ligand-1 checkpoint inhibition-associated bullous pemphigoid: a propensity-matched retrospective cohort study.程序性死亡受体-1和程序性死亡配体-1检查点抑制相关的大疱性类天疱疮：一项倾向匹配的回顾性队列研究。

Br J Dermatol. 2024 Jul 16;191(2):299-300. doi: 10.1093/bjd/ljae172.

2

A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.一例纳武利尤单抗诱导的大疱性类天疱疮：程序性细胞死亡蛋白 1/程序性死亡配体 1 抑制剂相关皮肤毒性的综述及诊断与管理建议。

Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.

3

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.抗 PD-1 和抗 PD-L1 治疗相关的大疱性疾病：一项回顾性分析，评估了临床和组织病理学特征、频率以及对癌症治疗的影响。

J Am Acad Dermatol. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. Epub 2018 Jul 17.

4

Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor.病例报告：低剂量白细胞介素-2：一种治疗由PD-1/PD-L1抑制剂引起的以毛囊周围水疱为主的大疱性类天疱疮的方法。

Front Immunol. 2024 Dec 10;15:1496413. doi: 10.3389/fimmu.2024.1496413. eCollection 2024.

5

Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A case series of 13 patients.抗程序性细胞死亡蛋白 1 和抗程序性细胞死亡配体 1 治疗相关的大疱性类天疱疮：13 例病例系列。

Australas J Dermatol. 2023 Feb;64(1):131-137. doi: 10.1111/ajd.13960. Epub 2022 Dec 13.

6

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1.靶向 PD-1 和 PD-L1 的免疫检查点抑制剂相关的自身免疫性大疱性皮肤病。

Cancer Immunol Res. 2016 May;4(5):383-9. doi: 10.1158/2326-6066.CIR-15-0123. Epub 2016 Feb 29.

7

Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system.

J Dermatol. 2025 Feb;52(2):309-316. doi: 10.1111/1346-8138.17517. Epub 2024 Oct 26.

8

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.PD-1 和 PD-L1 抑制剂相关大疱性类天疱疮的研究综述。

Int J Dermatol. 2018 Jun;57(6):664-669. doi: 10.1111/ijd.13984. Epub 2018 Apr 6.

9

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.癌症患者接受免疫检查点抑制剂治疗与大疱性类天疱疮的关联：一项系统评价。

JAMA Dermatol. 2022 Aug 1;158(8):933-941. doi: 10.1001/jamadermatol.2022.1624.

10

De novo autoimmune connective tissue disease and mortality in patients treated with anti-programmed death receptor-1 and anti-programmed death-ligand 1 therapy: a population-level cohort study.抗程序性死亡受体-1 和抗程序性死亡配体 1 治疗后新发自身免疫性结缔组织病和死亡率：一项基于人群的队列研究。

Br J Dermatol. 2024 Aug 14;191(3):460-462. doi: 10.1093/bjd/ljae184.

引用本文的文献

1

Associated factors related to production of autoantibodies and dermo-epidermal separation in bullous pemphigoid.大疱性类天疱疮中与自身抗体产生及皮肤表皮分离相关的因素。

Arch Dermatol Res. 2025 Jan 24;317(1):303. doi: 10.1007/s00403-024-03760-0.